Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
🤣 learn to read filings, parameters haven’t even come close to being able to issue shares yet…..
22k shares traded today…. Dilution 🤦♂️
😂 💀
For the latest I watch:
https://www.stemcellsgroup.com/press-releases/
Lots of good intel there...
Interested in your take on the recent movement here. Considering your history with the stock and all.
You’ve completed all the steps?
You should contact MSSV IR….. they may be able to help you….
investor.relations@mssvinc.com
I’ve owned it since before the LAHO buy back. The push to .35 was a result of the buyback……. Then, they squandered that catalyst by staying quiet…. Then, with extremely low volume, sank to sub penny…. But it’s easy to see what can happen here if they can get even a little interest.
My take? They took over LAHO to go public, the interest vastly exceeded any expectations and it ran hard, the run up attracted the SEC which shut them down due to delinquency, they moved over to MSSV, but don’t want to leave LAHO in the lurch, so the buy back, which was costly….. when they completed the SPAC, the revs were nothing the market dreamed…. They decided to stay silent, hence the slow deflation…. In the meantime, they have expanded and grew revenue without new funding….. potentially, they could make a ton of money. The new funding deal is interesting in that it’s not advantageous to the investor unless volume returns and PPS is consistent or goes higher.
A pump and dilution is a for sure thing here, how high it actually rises will depend on execution.
I think it’s a fun bet at this point
I am still waiting on the laho-payment...
So you got some or had some from before? This ran to .35 on 4 day jaunt not long ago.
Did you read the terms? They get their puts for 80% of the market price…. Not the average pps for 10 days, market price at time of execution…. They can’t just dump em on the market, no way will the investor execute in the current conditions, or pps. They wouldn’t even be able to unless there are 10 days like today in a row, cause min transaction has to be $10,000, and they can only pull out 250% of the average daily dollar volume over previous 10 days.
But I agree, a big pump will be required to access this funding and keep the investor protected.
Wonder what they got for that after being completely silent for 2 years!?!? Better be big.
You obviously have no clue what you are talking about… I trade and make money. :)
I also don’t sit around reading filings and waiting to poach on investors of stocks I’m not a shareholder in.
I read filings on stocks I’m meaningfully invested in. Picked these up after LAHO payout and haven’t paid much attn.
Yeah. It’s called “front loading”.
Have you read the s-1? I am assuming no, becuase you don’t read filings.
Fairly significant pre-pump action then.
Nah. Not at all. As I said…. Read the filings. There is a ton of dilution just about ready per the approved s-1.
Pump time
Still going unnoticed?
Offering approved. Due for a pump.
Read the filings
Seems like it. Anyone have an update or idea why?
Do we have a pulse yet ?... sure would like to see this come back to life.
On E*Trade, I had to go to the transaction history, print it out, and figure out my cost basis….. total money in divided by total shares bought, kind of a pain in the ass…. Gave it to my tax man, and he said perfect.
Im getting rich too richme
Not me. Still have not filed my 2022 tax return. I know what I received but do not know how much my shares cost. Unfortunately, TDA, did not list the transfer out either; the stock just disappeared with out trace.
To risky to ignore the return on investment.
If you hear anything please post it for all of us to know.
So, I see you're still a dumbass that invested in a scam. I'm not the one to blame. Blame the lying fraudsters and yourself for buying their bullshit...
Caveat Emptor!!
..
.
So I see you are still a big jerk ther tdpocketknife
This is still the same garbage its always been.
Caveat Emptor
..
.
Would have thought the last PR would have a filing. Idk, maybe I’m just used to too many fluff pr type filings from other tickers that I’m expecting to see info on the otc site.
It sure don’t look good…. It all stems from the LAHO share buy back, I’m still trying to figure out why someone would put up 10 million dollars for this company…. Not attracting shareholders won’t pay it back, that’s for sure.
The amount of debt will cripple them…
I’m not a huge fan of the way they communicate through only their website, but which articles do you believe they need to file an 8k for? Everything they have PR’d on their website is part of their stated business model, no material change/deviation, and by posting it to their website, they have made it publicly available….. again, I don’t agree with their method of informing the market, and hope they will soon actually start talking to shareholders in a more direct way.
Wise advice. Would still like an answer to my original question though.
I'm still buying. My daddy always taught me to buy low & sell high...
Looking into this… Is there a reason there’s no 8k’s associated with these press releases on MSSV OTC site? They seem disassociated since there’s no filings…
You have to watch GSCG site for updates. https://www.stemcellsgroup.com/press-releases/
How about MSSV renamed GSCG
Still no heart beat... I will check back in a week.
Loan due in full in two weeks. $111,470 plus 12% compounded interest.
https://www.sec.gov/Archives/edgar/data/1760026/000121390023029942/f10k2022ex10-10_mesonumis.htm
Caveat Emptor!!
..
.
Lol, I guess they do!
“The merger will never go through”
“They’ll never pay back LAHO shareholders”
“They’ll never file audited financials”
“Caveat emptor”
ROFL
Above are All con statements that have been running for 5+ years!
Real management
MSSV is real, with real revenues, the debt is from buying back LAHO shares, admirable to do in my opinion, but puts them behind the 8 ball until their revenues can accelerate.
Wasted 5 years dragging this company
Done deal…. For quite some time now, check their latest Annual and Quarter, revs from Global Stem Cell group included in them.
Must be fun to con for a living...
Merger with GSCG still on the table?!
Exciting stuff... this should start to warm up soon.
LAS VEGAS, NV, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a regenerative medicine company is pleased to announce that it will be undergoing a name change from Meso Numismatics Inc. to Regenerative Medical Technology Group Inc. to better reflect the company’s business. The Company will also change its authorized shares outstanding from the current 6.5 billion to 100 million shares. Please see the Information Statement on Schedule 14C filed by the Company on February 2, 2024, and other Company filings at www.sec.gov.
About Meso Numismatics: Meso Numismatics Corp is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun and is currently building another one in Dubai. The Company distributes stem cells and other regenerative based cell lines, and equipment internationally and also specializes in education and training physicians in the area of regenerative medicine.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
Forward-Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
The Cancun clinic is currently active and is finalizing its full build out, which will double its footprint by the end of February. The clinic is also comprised of a lab where stem cell cultures can be produced. The Cancun clinic currently offers numerous procedures for multiple indications including: hormone replacement, autoimmune, neurodegenerative, osteoarthritis, cardiovascular, aesthetic/anti-aging, hair transplant, sports medicine, spinal cord injury, MS, and autism. The Company is in the process of building out a clinic in Dubai that will offer similar procedures to those in the Cancun location. The Dubai clinic is expected to be fully operational by the end of the second quarter of this year.
The Company plans to close on two additional locations for new clinics, one by the end of the third quarter and one by the end of the fourth quarter of this year. Both of these clinics are expected to be operational by the end of the second quarter of 2025.
The Company also has a collaboration with an Istanbul based clinic where the Company refers patients and receives patient referrals on various patient procedures.
The Company operates in the stem cell therapy market, which is expected to grow from $11.2 billion in 2022 to $31.4 billion by 2030 according to Precedence Research. The Company has also entered the exosome market, which is expected to grow from $250 million in 2022 to $3.2 billion by 2032 according to Global Market Insights.
The Company is actively collaborating with leading research institutions, universities, and industry experts to accelerate the development and commercialization of regenerative medical solutions. These partnerships create a collaborative ecosystem that fosters scientific excellence and ensures that the Company remains at the forefront of innovation, contributing to medical advancements and expanding its range of products. With a global vision, the Company is dedicated to making a positive impact on healthcare worldwide. The company is exploring opportunities to expand its reach and make its cutting-edge medical procedures accessible to patients across borders.
"We are thrilled to be at the forefront of regenerative medicine, bringing hope to patients and pushing the boundaries of what is possible in biotechnology. Our commitment to innovation and collaboration underscores our mission to make a lasting impact on the lives of individuals facing challenging medical conditions," said David Christensen, CEO and President of the Company.
The driving forces behind Global Stem Cells Group's strategy to increase revenue in 2024 involve a multifaceted approach within the rapidly expanding stem cell therapy market. As the wholly-owned subsidiary of the Company, Global Stem Cells Group specializes in cutting-edge stem cell research collaborations and physician training. The key components contributing to revenue growth include:
Certified Training Courses for Physicians - Offering specialized and certified training courses to physicians, ensuring they are equipped with the latest knowledge and skills in stem cell therapies. The Company is internationally recognized as an expert in the field of stem cells and regenerative medicine.
Manufacturing and Sales of the Latest Technology, Supplies, and Equipment - Engaging in the production and sale of state-of-the-art technology, supplies, and equipment related to stem cell applications, catering to the needs of medical professionals in the field.
Research and Development of Clinical Protocols - Investing in research and development collaborations to create advanced clinical protocols for stem cell applications, enhancing the efficacy and safety of treatments.
Regenerative Medical Clinics - Cancun, Dubai, and Istanbul, Provide standardized regenerative medical treatments. These treatments cover a spectrum of health issues, including musculoskeletal disorders, autoimmune diseases, aesthetics, and anti-aging.
Franchising Network of Regenerative Medical Practitioners - Establishing a network of franchised regenerative medical practitioners, potentially increasing the geographical reach and accessibility of stem cell treatments. Currently 26 clinics in 21 countries carry the Company's banner. This allows the Company to raise its global profile and branding and assist the company in bringing patients to its own clinics.
Turnkey Solutions for Stem Cell Processing Center Installation & Management - Offering comprehensive complete solutions for the installation and management of stem cell processing centers, providing a one-stop solution for practitioners entering the field.
By diversifying into these key areas Global Stem Cells Group aims to tap into various aspects of regenerative medicine, creating revenue streams through education, product sales, research, patient services, and strategic partnerships within the stem cell therapy market.
"We are excited to announce our significant growth across multiple channels, showcasing the strength and diversity of our business. The success in training, product sales, equipment sales, and patient procedures reflects our commitment to excellence in every facet of regenerative medicine," said Benito Novas, CEO and Founder of Global Stem Cells Group.
This press release should be read in conjunction with all of the Company's filings on www.sec.gov
About Meso Numismatics: Meso Numismatics, Inc. is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun and is currently building another one in Dubai. The Company distributes stem cells and other regenerative based cell lines and equipment internationally and also specializes in educating and training physicians in the area of regenerative medicine.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |